Earnings Sentiment

Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.

Please consider a small donation if you think this website provides you with relevant information  

    

Sentiment Distribution

   

Earnings Call Transcript Word Cloud

     

Bullish Statements during Earnings call

Statement
For the physician, generating more revenue and patients to the clinic, for the patient, driving a better clinical outcome
With our strengthened balance sheet and improved profitability, rebuilding DTC is our top strategic priority and will provide improved profitable near-term growth
These value-add services, which have been there for years have proved to be very successful in driving the business from a standstill, and I'm using 2018 as a standstill, and I'm using 2021 as a standstill because there was no DTC prior to 2018 for a few years, and there was no prior to 2021 because of COVID-19, driving it within the following fiscal year to be very productive
It has been shown before by myself and the team in STRATA that we can vastly increase the unit economics and margins in the business
This turnaround helped in shifting the business to become a cash flow positive, growing the domestic and international installed base and the corresponding revenue streams, eliminating costs in noncore and noncore activities, enhancing the technology by launching new products and filing new patents and making sure the platform was ready for adding additional businesses, which in turn, allowed the company to successfully cross the COVID-19 challenge and be prepared for the core business growth and acquisitions that followed in 2021
As you will see during my remarks later, I believe this will directly increase our recurring revenue and unit utilization thereby increasing our gross profit margins
The procedure itself is clinically proven and has been working very nicely for several years prior to the time the company has acquired it
The goal will be to drive improved margins through increasing utilization as our products generate incremental recurring revenue, coupling the approach with the fully integrated suite of services that supports the partner clinics
Our new marketing initiatives, along with strategic management of our installed base will support rebuilding recurring revenue growth and margin expansion over the long-term
And by bringing back direct-to-consumer advertisement, we can vastly enhance the unit economics
As you can see here, non-GAAP adjusted EBITDA improved 21% year-over-year
I'm confident that with the new markets initiated by – in the past three years, this trend will be further strengthened
As evidenced over the past few years, the international installed base of over 1,400 devices has proven to be able to provide a solid revenue stream of capital equipment sales, service and device placements
We believe we are well equipped for this change and are optimistic about the future of STRATA
We're very encouraged by the improving trends of our business through the third quarter
I believe there is a much better opportunity in placing TheraClearX with our clinical dermatologist network and leveraging our already established suite of services, helping them use insurance reimbursement codes to reduce out-of-pocket costs to the patients and provide better clinical outcomes, thereby increasing patient volumes and utilization
And today, with an installed base that is larger by 25%, driving that average revenue per device will further increase not only unit economics, but the top line revenue
I think the change that we're trying to do now is going to result, if successful, in growth and utilization, unit economic and by that, expanding the bottom line results
I think moving forward, we tend to be successful with deploying this as a reimbursable procedure because we have all of the support mechanism to give the suite of services and provide these services to the clinics and to the patients
The addition of recurring revenue on – into 2024 is going to potentially drive the operating margins up and by that drive cash flow from operations to be positive again
This growth stems from improved cash cost effectiveness with G&A and sales and marketing expenses decreasing 16.5% year-over-year to $5.3 million
TheraClearX offers a compelling solution for an acne software that is reimbursable when prescribed to treat active inflammatory lesions
As we prepare to shift back to a DTC model, we aim to reduce total revenue cost and increase margins
We ended the third quarter in a solid cash position with $8.5 million in cash, cash equivalents and restricted cash as of September 30, 2023
The leads shown in purple represents the number of patients demonstrating interest in the solution of the XTRAC excimer laser procedure offering the benefits to them
We remain intently focused on executing our strategic plan to drive profitable revenue growth and thereby enhance the shareholder value
We – and as you can look through in my prepared remarks, we believe that the deployment of these devices with partners that are actually utilizing the reimbursement code is going to make the expansion of that procedure easier, both for the company as well as for the physicians and the patients because by utilizing the full suite of services that the company has starting from driving patients to the clinics and supporting the clinics through reimbursement, the reimbursement process and as well as supporting the patients in their own payments is going to help drive that revenue from our perspective, but also the deployment of devices and usage by physicians and the number of patients being treated
Accumulating over 30 years of experience in health care and medical devices, my vision moving forward is to concentrate on advancing and expanding our core products XTRAC, VTRAC and TheraClearX by reintroducing our direct-to-consumer further referred to as DTC initiative that was in place during my previous three tenures and allowed for clear growth of that business
The company has undergone a recent reorganization of its Board of Directors to streamline its structure and enhance its alignment with the company's strategic objectives
As we close our third quarter, I want to reiterate our top priority is to reignite the customer experience and value to our clinical partners while improving the quality of life for their patients
       

Bearish Statements during earnings call

Statement
For the three months ended, total revenues were $8.9 million, down 6% from $9.4 million in the prior year period
I believe that the deemphasis of patient marketing and support services during the period between 2021 and today, severely impacted the product utilization because STRATA was no longer driving patients to the physician's offices and consequently offered less partner support services to the clinics, which in turn impacted our partnership relationships with the physicians
And then again, in 2022, these metrics have trended down
As you have seen in the past few quarters since the deployment of this model, the expansion was slower in terms of expansion in a number of clinics and was also limited in the returns per clinic in the sales or revenue per device per clinic
And when it didn't work, they pulled back
One, the reduction in the number of patients that were put into treatment by the DTC process
   

Please consider a small donation if you think this website provides you with relevant information